Adjust Font Sizing:

NN Blog

Stay Hydrated This Summer

While exposure to light is supposed to promote “alertness”, it’s not uncommon to feel tired or even sluggish after spending time outside. There are many factors that […]

Listening Journey: Our Collective Voice Matters

Last year, Narcolepsy Network began a “Listening Journey” to better understand our organization’s individual and collective interests. We also sought out the perspectives of medical professionals and industry […]

Clinical Research Matters: Takeaways From World Sleep Congress 2022

by Keith Harper, Board President Last week, Amy Kant, Transition Director, and I traveled to Rome for the 2022 World Sleep Congress, an event put together by […]

Transition Leadership Announcement

The voice of people with narcolepsy is the heart of Narcolepsy Network. Since we announced leadership changes in February, we are continuing to deliver on current programs […]

An Update from the Board of Directors

Dr. Eveline Honig was with Narcolepsy Network for the last 16 years, aiding in its mission to provide education, support, and advocacy for patients and families impacted […]

Update on the COVID-19 Vaccine

We asked Dr. Michael Thorpy, a member of our Medical Advisory Board from the Sleep-Wake Disorders Center in New York if people with narcolepsy should get the […]

Donate to Make Twice the Impact

Thanks to a few generous donors, if you make a donation before January 1, 2021, they will match your gift up to $10,000. This means your donation […]

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Avadel Pharmaceuticals plc announced the submission of its New Drug Application to the US Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium […]

Support Us on #GivingTuesday

This year has been one to remember! While many of us are still struggling to find a new normal, we are proud of the programs we have […]

Positive Results from IH Phase 3 Study of Xywav

Jazz Pharmaceuticals plc announced positive top-line results from their Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of […]